These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 27384149

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
    Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Ueki Y, Migita K, Mizokami A, Aoyagi K, Eguchi K.
    Mod Rheumatol; 2011 Aug; 21(4):370-4. PubMed ID: 21240618
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients.
    Nakajima T, Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ito H, Yamamoto W, Kitagori K, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Matsuda S, Morinobu A.
    Rheumatol Int; 2022 Nov; 42(11):1983-1991. PubMed ID: 34241658
    [Abstract] [Full Text] [Related]

  • 9. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Ueki Y, Migita K, Mizokami A, Origuchi T, Aoyagi K, Eguchi K.
    Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS, Aletaha D.
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [Abstract] [Full Text] [Related]

  • 11. Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab.
    Hoshi D, Nakajima A, Shidara K, Seto Y, Tanaka E, Taniguchi A, Momohara S, Yamanaka H.
    Mod Rheumatol; 2013 Nov; 23(6):1205-10. PubMed ID: 23456321
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
    Mori S, Yoshitama T, Abe Y, Hidaka T, Hirakata N, Aoyagi K, Ueki Y.
    Rheumatology (Oxford); 2019 Jul 01; 58(7):1274-1284. PubMed ID: 30793749
    [Abstract] [Full Text] [Related]

  • 14. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI.
    Kaneko A, Kida D, Saito K, Tsukamoto M, Sato T.
    Rheumatol Int; 2012 Nov 01; 32(11):3631-7. PubMed ID: 22127466
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T, Lie E, Norvang V, Lexberg ÅS, Rødevand E, Krøll F, Kalstad S, Olsen IC, Kvien TK.
    J Rheumatol; 2016 Apr 01; 43(4):716-23. PubMed ID: 26879358
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.
    Cannon GW, Wang BC, Park GS, Koenig A, Collier DH, Keystone EC.
    Clin Exp Rheumatol; 2013 Apr 01; 31(6):919-25. PubMed ID: 24237999
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.